NO20060114L - Naftylenderivater som cytokrom P450-inhibitorer - Google Patents

Naftylenderivater som cytokrom P450-inhibitorer

Info

Publication number
NO20060114L
NO20060114L NO20060114A NO20060114A NO20060114L NO 20060114 L NO20060114 L NO 20060114L NO 20060114 A NO20060114 A NO 20060114A NO 20060114 A NO20060114 A NO 20060114A NO 20060114 L NO20060114 L NO 20060114L
Authority
NO
Norway
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
NO20060114A
Other languages
English (en)
Norwegian (no)
Inventor
Vanessa Smith
Anthony Nigro
Mark Mulvihill
Cara Cesario
Patrica Anne Beck
Arlindo L Castelhano
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of NO20060114L publication Critical patent/NO20060114L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
NO20060114A 2003-07-10 2006-01-06 Naftylenderivater som cytokrom P450-inhibitorer NO20060114L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
PCT/US2004/022282 WO2005007631A1 (fr) 2003-07-10 2004-07-12 Derives de naphtylene constituant des inhibiteurs du cytochrome p450

Publications (1)

Publication Number Publication Date
NO20060114L true NO20060114L (no) 2006-02-09

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060114A NO20060114L (no) 2003-07-10 2006-01-06 Naftylenderivater som cytokrom P450-inhibitorer

Country Status (15)

Country Link
EP (1) EP1654236A1 (fr)
JP (1) JP4832295B2 (fr)
KR (1) KR20060052799A (fr)
CN (1) CN1819996B (fr)
AU (1) AU2004257257B2 (fr)
BR (1) BRPI0412424A (fr)
CA (1) CA2532078A1 (fr)
IL (1) IL172812A0 (fr)
IS (1) IS8223A (fr)
MX (1) MXPA06000401A (fr)
NO (1) NO20060114L (fr)
RU (1) RU2363696C2 (fr)
SG (1) SG144941A1 (fr)
UA (1) UA87822C2 (fr)
WO (1) WO2005007631A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696899A1 (fr) * 2003-12-17 2006-09-06 Allergan, Inc. Procedes permettant de traiter des troubles sensibles au retinoide au moyen d'inhibiteurs selectifs de cyp26a et de cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US8513291B2 (en) 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
KR20180039185A (ko) * 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EP2651905B1 (fr) * 2010-12-13 2017-07-19 Innocrin Pharmaceuticals, Inc. Composés inhibiteurs de métalloenzyme
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
WO2014015137A2 (fr) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions et méthodes de traitement de maladies dysprolifératives
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (fr) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft Dérivés de 2-[2-phényl-1-(sulfonylméthyl)vinyl]-imidazo[4,5-b]pyridine et composés apparentés utilisés comme pesticides en protection des plantes
EP3568395A1 (fr) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Dérivés hétérocycliques utilisés comme pesticides
TW201837036A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（一）

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (fr) * 1960-05-04
NL131915C (fr) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
ATE293102T1 (de) * 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類

Also Published As

Publication number Publication date
CN1819996B (zh) 2010-10-27
RU2363696C2 (ru) 2009-08-10
WO2005007631A1 (fr) 2005-01-27
EP1654236A1 (fr) 2006-05-10
KR20060052799A (ko) 2006-05-19
UA87822C2 (ru) 2009-08-25
JP4832295B2 (ja) 2011-12-07
SG144941A1 (en) 2008-08-28
MXPA06000401A (es) 2006-03-17
AU2004257257B2 (en) 2011-05-12
IL172812A0 (en) 2006-06-11
CA2532078A1 (fr) 2005-01-27
CN1819996A (zh) 2006-08-16
BRPI0412424A (pt) 2006-09-05
RU2006103996A (ru) 2006-07-10
JP2007523866A (ja) 2007-08-23
AU2004257257A1 (en) 2005-01-27
IS8223A (is) 2006-01-10

Similar Documents

Publication Publication Date Title
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
NO20054852L (no) GFAT inhibitorer
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
NO20070295L (no) Nye CIS-imidazoliner
WO2007130075A8 (fr) Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
NO20061454L (no) Compounds having CRTH2 antagonist activity
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
JO2282B1 (en) Oxazole derivatives
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
NO20051263L (no) Ny anvendelse av benzotiazolderivater
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
DE60107820D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
EP2639229A3 (fr) Dérivé de thiazole et son utilisation en tant qu'inhibiteur VAP-1
SE0301232D0 (sv) Novel use
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
WO2008008701A3 (fr) Composés thérapeutiques
AU2002215932A1 (en) Nitroderivatives as drugs for diseases having an inflammatory basis
NO20065873L (no) 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application